Open innovation: A paradigm shift in pharma R&amp;D?

Schuhmacher, Alexander; Gassmann, Oliver; Bieniok, Doria; Hinder, Markus; Hartl, Dominik

doi:10.1016/j.drudis.2022.05.018

Cited by 23 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the dramatic investment increase and continuous technological advance during the past two decades (15), researchers are highly curious about how clinical success rate (ClinSR) is affected over time. Herein, the dynamic ClinSRs of 15 time-windows from the beginning of 21st century to now were therefore systematically assessed.…”

Section: Resultsmentioning

confidence: 99%

Dynamic Clinical Success Rates for Drugs in the 21st Century

Zhou,

Zhang,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

In clinical drug development, two fundamental questions remain unanswered: what is the success rate of drugs in clinical trial? how does such rate change over time? Herein, a systematic analysis on the dynamic change of drugs' clinical success rates (ClinSRs) using data from 20,398 clinical trial pipelines of 9,682 unique molecular entities during the past two decades was presented. Our analysis discovered that ClinSRs had been declining since the beginning of 21st century, and hit the bottom in recent years even substantially lower than previous estimates. In-depth assessments further reported great variation among the ClinSRs of various diseases, developmental strategies, and drug modalities. A platform ClinSR.org (http://ClinSR.idrblab.org/) was finally constructed online to enable the illustration of how ClinSR dynamically changes over time, automated update of ClinSR for the coming decade, and customized calculation of ClinSRs for any drug group of interest. In sum, this study met the critical demand for accurate, timely and persistent assessment of ClinSR, for now and the future, to aid pharmaceutical and economic decision making.

show abstract

Section: Resultsmentioning

confidence: 99%

Dynamic Clinical Success Rates for Drugs in the 21st Century

Zhou,

Zhang,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…To achieve this goal, we are sharing our best tool compounds and beyond via different initiatives: https://www.theSGC.org, https://EUbOPEN.org, and https://opnMe.com. 7,36,37 The driver behind our open science initiatives is the recognition that, "No matter who you are, most of the brightest brains work for someone else," and not only in your own organization. Our open science initiatives seek to lift barriers between academic researchers and high-quality, industrial technology, and, in doing so, chart a new path for pharmaceutical open innovation.…”

Section: Boehringer Ingelheim Opnmementioning

confidence: 99%

“…In addition, industry (outside the umbrella of Target 2035) hosts open innovation programs wherein the global academic research community can access first-in-class compounds, by proposing exciting hypothesis-driven science. Noteworthy examples are the AACR-Bayer Innovation and Discovery Grants, 35 Boehringer Ingelheim's OpnMe, 7,36,37 Merck KGaA's Open Innovation Portal, 38 Co-Create Knowledge for Pharma Innovation with Takeda Funding, 39 and Novo Nordisk's Compound Sharing platform. 40 In the following section, representatives from the private sector independently added granularity to their company's contributions to open science.…”

Section: Introductionmentioning

confidence: 99%

“…6 We are, however, confident that, with open and unrestricted science and a global federated effort from academia and industry, we will meet this challenge. [7][8][9][10][11][12][13][14] Target 2035 aims to create an open and collaborative ecosystem through forming public-private partnerships (PPPs), hosting virtual events via https://target2035.net, 15 open science communities such as Just One Giant Lab, 16 and contributing to the organization of in-person workshops such as at the International Chemical Biology Society conference (https://icbs2022.chemical-biology.org/).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Target 2035 – an update on private sector contributions

Ackloo

Antolín

Bartolomé³

et al. 2023

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Open innovation (OI) is a widely used approach in various managerial fields and industries that facilitates the integration of knowledge inflow and outflow and research and development (R&D) [ 1 ]. Examples of its application include pharmaceutical R&D [ 2 ], blockchain-enabled value cocreation [ 3 ], and the collaborative community of mobile health in the health care industry [ 4 ]. OI encompasses both pecuniary and nonpecuniary models, which serve different purposes beyond just business operations.…”

Section: Introductionmentioning

confidence: 99%

Fortifying Health Care Intellectual Property Transactions With Blockchain

Liang¹,

Lee²,

HAN³

2023

J Med Internet Res

View full text Add to dashboard Cite

Background Intellectual property (IP) is a substantial competitive advantage in the health care industry. However, the COVID-19 pandemic highlighted the need for open innovation and collaboration for the greater good. Despite this, the industry faces challenges with innovation owing to organizational and departmental barriers. A secure platform is necessary to facilitate IP sharing without compromising the rights of IP owners. Objective This study proposes a blockchain-based framework to secure IP transactions in health care and bring social impact. Methods This study reviews existing researches, publications, practical cases, firm and organization websites, and conferences related to blockchain technology, blockchain in health care, blockchain in IP management, IP pledge research, and practice of IP management blockchain. The platform architecture has 7 components: pledgers, advanced research technology (ART), IP pledge platforms, IP databases, health care research, seeking ART, and transaction condition setting. These components work together seamlessly to support the sharing and pledging of ART and knowledge, while ensuring the platform’s transparency, security, and trust. Results The open IP pledge framework can promote technology dissemination and use, reduce research and development costs, foster collaboration, and serve the public interest. Medical organizations’ leadership and support and active participation from stakeholders are necessary for success. By leveraging blockchain technology, the platform ensures tamper-proof and transparent transactions and protects the rights of IP owners. In addition, the platform offers incentive mechanisms through pledge tokens that encourage stakeholders to share their ART and contribute to the platform. Conclusions Overall, the proposed framework can facilitate technological innovation, tackle various challenges, and secure IP transactions. It provides a secure platform for stakeholders to share their IP without compromising their rights, promoting collaboration and progress in the health care industry. The implementation of the framework has the potential to revolutionize the industry’s approach to innovation, allowing a more open and collaborative environment driven by the greater good.

show abstract

Open innovation: A paradigm shift in pharma R&D?

Cited by 23 publications

References 40 publications

Dynamic Clinical Success Rates for Drugs in the 21st Century

Dynamic Clinical Success Rates for Drugs in the 21st Century

Target 2035 – an update on private sector contributions

Fortifying Health Care Intellectual Property Transactions With Blockchain

Contact Info

Product

Resources

About